Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors

Abstract

Ovarian cancer (OC) ranks as the fifth leading factor for female mortality globally, with a substantial burden of new cases and mortality recorded annually. Survival rates vary significantly based on the stage of diagnosis, with advanced stages posing significant challenges to treatment. OC is primarily categorized as epithelial, constituting approximately 90% of cases, and correct staging is essential for tailored treatment. The debulking followed by chemotherapy is the prevailing treatment, involving platinum-based drugs in combination with taxanes. However, the efficacy of chemotherapy is hindered by the development of chemoresistance, both acquired during treatment (acquired chemoresistance) and intrinsic to the patient (intrinsic chemoresistance). The emergence of chemoresistance leads to increased mortality rates, with many advanced patients experiencing disease relapse shortly after initial treatment. This review delves into the multifactorial nature of chemoresistance in OC, addressing mechanisms involving transport systems, apoptosis, DNA repair, and ovarian cancer stem cells (OCSCs). While previous research has identified genes associated with these mechanisms, the regulatory roles of non-coding RNA (ncRNA) and nuclear receptors in modulating gene expression to confer chemoresistance have remained poorly understood and underexplored. This comprehensive review aims to shed light on the genes linked to different chemoresistance mechanisms in OC and their intricate regulation by ncRNA and nuclear receptors. Specifically, we examine how these molecular players influence the chemoresistance mechanism. By exploring the interplay between these factors and gene expression regulation, this review seeks to provide a comprehensive mechanism driving chemoresistance in OC.

Keywords

Ovarian cancer / drug resistance / nuclear receptor / non-coding RNA / ovarian cancer stem cells

References

[1] WHO. Global Cancer Observatory. Available from: https://gco.iarc.fr/. [Last accessed on 23 Feb 2024]

[2] City of Hope. Ovarian cancer stages. Available from: https://www.cancercenter.com/cancer-types/ovarian-cancer/stages. [Last accessed on 23 Feb 2024]

[3] American Cancer Society. Survival rates for ovarian cancer. Available from: https://www.cancer.org/cancer/types/ova rian-cancer/detection-diagnosis-staging/survival-rates.html. [Last accessed on 26 Feb 2024]

[4] Wang Z. DNA Damage Repair Pathways and Repair of Cisplatin-Induced DNA Damage. Available from: https://www.semanticscholar.org/paper/DNA-Damage-Repair-Pathways-and-Repair-of-DNA-Damage-Wang-Zhu/de35aacc1d2ece7f2a067b86a9367176402e40c0. [Last accessed on 26 Feb 2024]

[5] Tossetta G.Metformin improves ovarian cancer sensitivity to paclitaxel and platinum-based drugs: a review of in vitro findings.Int J Mol Sci2022;23:12893 PMCID:PMC9654053

[6] Patel A,Matsuzaki S,Sood AK.Emerging trends in neoadjuvant chemotherapy for ovarian cancer.Cancers2021;13:626 PMCID:PMC7915369

[7] Marchetti C,Romito A.Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments.Semin Cancer Biol2021;77:144-66

[8] Tossetta G.Natural and synthetic compounds in ovarian cancer: a focus on NRF2/KEAP1 pathway.Pharmacol Res2022;183:106365

[9] Tossetta G,Goteri G,Ciavattini A.The role of NQO1 in ovarian cancer.Int J Mol Sci2023;24:7839 PMCID:PMC10178676

[10] Yang Y,Sun Y,Zhao Z.Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2.Onco Targets Ther2019;12:897-906 PMCID:PMC6357888

[11] Yin L,Zeng R.Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.Oncogene2021;40:6772-85 PMCID:PMC8688329

[12] Villedieu M,Dutoit S.Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.Gynecol Oncol2007;105:31-44

[13] Wu X,Zhao P.MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.Proc Natl Acad Sci U S A2019;116:2961-6 PMCID:PMC6386650

[14] Kale J,Brito GC.Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance.EMBO Rep2018;19:e45235 PMCID:PMC6123645

[15] Inoue-Yamauchi A.EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X_L inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells.Biochem Biophys Res Commun2020;526:612-7

[16] Rizzo A,Garrone G.Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells.J Exp Clin Cancer Res2021;40:5 PMCID:PMC7780408

[17] Abedini MR,Yan X.Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.Oncogene2004;23:6997-7004

[18] Sapi E,Chen W.Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol.Oncol Res2004;14:567-78

[19] Ma JJ,Xin XY.XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.Eur J Obstet Gynecol Reprod Biol2009;146:222-6

[20] Zaffaroni N,Colella G.Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.Cell Mol Life Sci2002;59:1406-12

[21] Cohen S,Graiver D.Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.J Mol Med2013;91:357-68

[22] Bradley A,Ziebarth A.EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.Carcinogenesis2014;35:1100-9 PMCID:PMC4004201

[23] Matsuura K,Cocce K,Kornbluth S.Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.Oncogene2017;36:1698-706 PMCID:PMC5447866

[24] Abedini MR,Brun J,Gray DA.Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.Cancer Res2008;68:4511-7

[25] MacKay C,Ibrahim AFM.E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin.Cancer Res2014;74:2246-57 PMCID:PMC3990471

[26] Hu X,Xu L.Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.Cell Death Dis2019;10:104 PMCID:PMC6362125

[27] Schultz MJ,Wright JW,Landen CN.ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells.J Ovarian Res2013;6:25 PMCID:PMC3637436

[28] Connor JP,Kapur A.DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.BMC Cancer2012;12:176 PMCID:PMC3462721

[29] Shu J,Zhang D.Dynamic analysis of proteomic alterations in response to N-linked glycosylation inhibition in a drug-resistant ovarian carcinoma cell line.FEBS J2019;286:1594-605 PMCID:PMC7360092

[30] Zhang P,Shi B.Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.Cell Death Dis2014;5:e991 PMCID:PMC4040687

[31] Wang D,Li L.Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.J Toxicol Sci2019;44:47-56

[32] Cai M,Jin Y.hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2.Cell Death Discov2023;9:179 PMCID:PMC10250293

[33] Matei D,Shen C.Epigenetic resensitization to platinum in ovarian cancer.Cancer Res2012;72:2197-205 PMCID:PMC3700422

[34] Jurkovicova D,Gašparović AČ.DNA damage response in cancer therapy and resistance: challenges and opportunities.Int J Mol Sci2022;23:14672 PMCID:PMC9735783

[35] Patch AM, Christie EL, Etemadmoghadam D, et al; Australian Ovarian Cancer Study Group. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;521:489-94.

[36] Norquist B,Pennil CC.Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.J Clin Oncol2011;29:3008-15 PMCID:PMC3157963

[37] Dey G,Braley C.LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.J Ovarian Res2023;16:122 PMCID:PMC10294509

[38] Kondrashova O, Nguyen M, Shield-Artin K, et al; AOCS Study Group. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov 2017;7:984-98. PMCID:PMC5612362

[39] Rauth S,Atri P.Elevated PAF1-RAD52 axis confers chemoresistance to human cancers.Cell Rep2023;42:112043 PMCID:PMC10374878

[40] Berkel C.Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.Biochem Biophys Res Commun2021;570:74-81

[41] Sad LMAE,Elanwar NM.CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy.J Cancer Res Ther2021;17:1454-61

[42] Mesquita KA,Griffin M.ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.Gynecol Oncol2019;153:416-24

[43] Du P,Chen L,Wu Q.High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.Oncol Lett2016;12:857-62 PMCID:PMC4950824

[44] Gao M,Huang J.DOCK7 protects against replication stress by promoting RPA stability on chromatin.Nucleic Acids Res2021;49:3322-37 PMCID:PMC8034614

[45] Abdel-Fatah T,Abbotts R.Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.Int J Cancer2013;132:2778-86

[46] Zhang Z,Sun G.Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells.Int J Clin Exp Med2015;8:6687-701 PMCID:PMC4509152

[47] Miao J,Tang QL,Kai L.Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.Asian Pac J Cancer Prev2012;13:5007-10

[48] Al-Attar A,Fareed KR.Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.Br J Cancer2010;102:704-9 PMCID:PMC2837561

[49] Plumb JA,Sludden J,Brown R.Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.Cancer Res2000;60:6039-44

[50] Tian H,Xiao-Fei L,Juan C.Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.Clin Epigenetics2019;11:153 PMCID:PMC6822346

[51] Zheng Z,Yang B.SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer.Funct Integr Genomics2023;23:147

[52] Wang Q,Hu L,Zhang H.Hedgehog-Gli2 signaling promotes chemoresistance in ovarian cancer cells by regulating MDR1.Front Oncol2021;11:794959 PMCID:PMC8763667

[53] Tong X,Zhang Y,Wang X.Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients.Oncol Lett2019;18:22-8 PMCID:PMC6540457

[54] Wang JM,Zhang Q.ISG15 suppresses translation of ABCC2 via ISGylation of hnRNPA2B1 and enhances drug sensitivity in cisplatin resistant ovarian cancer cells.Biochim Biophys Acta Mol Cell Res2020;1867:118647

[55] Jung M, Gao J, Cheung L, et al; Australian Ovarian Cancer Study. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. Int J Cancer 2020;147:2225-38.

[56] Wang JQ,Yang Y.Establishment and characterization of a novel multidrug resistant human ovarian cancer cell line with heterogenous MRP7 overexpression.Front Oncol2021;11:731260 PMCID:PMC8498192

[57] He M,Jiang Q.Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.Mol Oncol2019;13:403-21 PMCID:PMC6360369

[58] Lukanović D,Kobal B.The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.Biomed Pharmacother2020;129:110401

[59] Li T,Zeng F.Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.Int J Clin Pharmacol Ther2017;55:774-80

[60] Mangala LS,Schmandt R.Therapeutic targeting of ATP7B in ovarian carcinoma.Clin Cancer Res2009;15:3770-80 PMCID:PMC2752981

[61] Petruzzelli R,De Cegli R.TFEB regulates ATP7B expression to promote platinum chemoresistance in human ovarian cancer cells.Cells2022;11:219 PMCID:PMC8774088

[62] Kalayda GV,Jaehde U.Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.J Inorg Biochem2012;116:1-10

[63] Lv X,Xue K.Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake.Mol Carcinog2019;58:794-807

[64] Blair BG,Adams PL,Safaei R.Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.Mol Pharmacol2010;77:912-21 PMCID:PMC2879916

[65] Wilkens S.Structure and mechanism of ABC transporters.F1000Prime Rep2015;7:14 PMCID:PMC4338842

[66] Barzegar S.Zinc finger proteins and ATP-binding cassette transporter-dependent multidrug resistance.Eur J Clin Invest2024;54:e14120

[67] Tian Y,Wang Y,Wang J.Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review).Int J Oncol2023;63:119 PMCID:PMC10546381

[68] Yin Y,Zhang F.Overcoming ABCB1-mediated multidrug resistance by transcription factor BHLHE40.Neoplasia2023;39:100891 PMCID:PMC10025992

[69] Sajid A,Ambudkar SV.Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters.Nat Rev Cancer2023;23:762-79

[70] Galetin A,Tweedie D.Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov 2024.

[71] Hille S,Riffelmann M.Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.Anticancer Drugs2006;17:1041-4

[72] Masanek U,Volm M.Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.Anticancer Drugs1997;8:189-98

[73] Pan J,Yao M.Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.Eur J Pharm Biopharm2019;136:18-28 PMCID:PMC6377860

[74] Yang X,Singh A.MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.Sci Rep2015;5:8509 PMCID:PMC4330541

[75] Sajid A,Murakami M.Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein.Proc Natl Acad Sci U S A2020;117:29609-17 PMCID:PMC7703596

[76] Vahedi S,Ambudkar SV.Global alteration of the drug-binding pocket of human P-glycoprotein (ABCB1) by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency.Biochem Pharmacol2017;143:53-64 PMCID:PMC5610938

[77] Pietilä M,Peuhu E.SORLA regulates endosomal trafficking and oncogenic fitness of HER2.Nat Commun2019;10:2340 PMCID:PMC6538630

[78] Kim JY,Lee JY.ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.Cell Death Dis2022;13:239 PMCID:PMC8924236

[79] Christie EL.Acquired chemotherapy resistance in ovarian cancer.Ann Oncol2017;28:viii13-5

[80] Miller JS,Rhoades JA.Targeting hedgehog-driven mechanisms of drug-resistant cancers.Front Mol Biosci2023;10:1286090 PMCID:PMC10634604

[81] Yin B,Liang J.The ABCB1 3435C > T polymorphism influences docetaxel transportation in ovarian cancer.J Int Med Res2019;47:5256-69 PMCID:PMC6997784

[82] Ohishi Y,Uchiumi T.ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.Clin Cancer Res2002;8:3767-75

[83] Ehrlichova M,Hrdy J.The association of taxane resistance genes with the clinical course of ovarian carcinoma.Genomics2013;102:96-101

[84] Wang Y,Li B,Huang C.The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer.Front Endocrinol2022;13:863541 PMCID:PMC9127157

[85] Varier L,Gamit N.An overview of ovarian cancer: the role of cancer stem cells in chemoresistance and a precision medicine approach targeting the wnt pathway with the antagonist sFRP4.Cancers2023;15:1275 PMCID:PMC9954718

[86] Chen DQ,Cao LQ.The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond.Drug Resist Updat2024;73:101062

[87] Terraneo N,Dubrovska A.Novel therapeutic strategies for ovarian cancer stem cells.Front Oncol2020;10:319 PMCID:PMC7090172

[88] Dyla M,Poulsen H.Structure and mechanism of P-type ATPase ion pumps.Annu Rev Biochem2020;89:583-603

[89] Ortiz M,Mitchell K.Mechanisms of chemotherapy resistance in ovarian cancer.Cancer Drug Resist2022;5:304-16 PMCID:PMC9255249

[90] Pan Z,Dokudovskaya S.The role of mTORC1 pathway and autophagy in resistance to platinum-based chemotherapeutics.Int J Mol Sci2023;24:10651 PMCID:PMC10341996

[91] Bai X,Reithmeier RAF.Structural biology of solute carrier (SLC) membrane transport proteins.Mol Membr Biol2017;34:1-32

[92] Holzer AK,Klomp LW.Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.Clin Cancer Res2004;10:6744-9

[93] Holzer AK,Katano K.The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.Mol Pharmacol2004;66:817-23

[94] Song M,Liu K.Therapeutic strategies to overcome cisplatin resistance in ovarian cancer.Eur J Med Chem2022;232:114205

[95] Yoshida H,Yamauchi M.Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.Anticancer Res2013;33:1409-14

[96] Bhartiya D,Sharma D.Heterogeneity of stem cells in the ovary. In: Birbrair A, editor. Stem cells heterogeneity in different organs. Cham: Springer International Publishing; 2019. pp. 213-23.

[97] Nowicki A,Wieczorkiewicz M.Ovarian cancer and cancer stem cells - cellular and molecular characteristics, signaling pathways, and usefulness as a diagnostic tool in medicine and oncology.Cancers2021;13:4178 PMCID:PMC8394875

[98] Testa U,Pasquini L,Pelosi E.Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells.Medicines2018;5:16 PMCID:PMC5874581

[99] Ahmed N,Raza A,Jubinsky PT.Ovarian cancer, cancer stem cells and current treatment strategies: a potential role of magmas in the current treatment methods.Cells2020;9:719 PMCID:PMC7140629

[100] Somasagara RR,Tripathi K.RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.Oncogene2017;36:6680-90 PMCID:PMC5709226

[101] Bareiss PM,Wang H.SOX2 expression associates with stem cell state in human ovarian carcinoma.Cancer Res2013;73:5544-55

[102] Seo EJ,Jang IH.Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer.Oncotarget2016;7:55624-38 PMCID:PMC5342441

[103] Wen Y,Huang Z,Wang Z.SOX2 is required to maintain cancer stem cells in ovarian cancer.Cancer Sci2017;108:719-31 PMCID:PMC5406610

[104] Xiang T,He L.Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133⁺ cancer stem-like cells in ovarian cancer.Oncogene2015;34:165-76

[105] Zhang S,Chan MW.Identification and characterization of ovarian cancer-initiating cells from primary human tumors.Cancer Res2008;68:4311-20 PMCID:PMC2553722

[106] Alvero AB,Holmberg JC,Brown D.Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells.Mol Cancer Ther2011;10:1385-93 PMCID:PMC3703662

[107] Nunes T,Leboeuf C.Targeting cancer stem cells to overcome chemoresistance.Int J Mol Sci2018;19:4036 PMCID:PMC6321478

[108] Ayub TH,Debald M.Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.Oncotarget2015;6:16437-48 PMCID:PMC4599280

[109] Nakamura K,Tanabe A.CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.Oncol Rep2017;37:3189-200 PMCID:PMC5442399

[110] Liu CL,Fan MH,Mao TL.Characteristics of CD133-sustained chemoresistant cancer stem-like cells in human ovarian carcinoma.Int J Mol Sci2020;21:6467 PMCID:PMC7554888

[111] Motohara T.Ovarian cancer stemness: biological and clinical implications for metastasis and chemotherapy resistance.Cancers2019;11:907 PMCID:PMC6678827

[112] Han T,Chen L.HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway.Cell Death Dis2023;14:606 PMCID:PMC10502110

[113] Alatise KL,Alexander-Bryant A.Mechanisms of drug resistance in ovarian cancer and associated gene targets.Cancers2022;14:6246 PMCID:PMC9777152

[114] McAuliffe SM,Wyant GA.Targeting notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.Proc Natl Acad Sci U S A2012;109:E2939-48 PMCID:PMC3491453

[115] Wang Z,Yang G.Cancer stem cell biomarkers and related signalling pathways.J Drug Target2024;32:33-44

[116] Meirelles K,Dombkowski D.Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.Proc Natl Acad Sci U S A2012;109:2358-63 PMCID:PMC3289387

[117] Królewska-Daszczyńska P,Smycz-Kubańska M,Mielczarek-Palacz A.Cancer stem cells markers in ovarian cancer: clinical and therapeutic significance (Review).Oncol Lett2022;24:465 PMCID:PMC9667454

[118] Chau WK,Mak AS,Wong AS.c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.Oncogene2013;32:2767-81

[119] Januchowski R,Sterzyſska K.Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.Int J Biochem Cell Biol2016;78:248-59

[120] Landen CN Jr,Katre AA.Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.Mol Cancer Ther2010;9:3186-99 PMCID:PMC3005138

[121] Alvero AB,Fu HH.Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.Cell Cycle2009;8:158-66 PMCID:PMC3041590

[122] Shi MF,Lu WG.Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line.Cell Mol Life Sci2010;67:3915-25

[123] Sriramkumar S,Huntington TD.Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.J Transl Med2022;20:246

[124] Ma H,Cui Z.Targeting ovarian cancer stem cells: a new way out.Stem Cell Res Ther2023;14:28 PMCID:PMC9926632

[125] Zhang L,Gao M.SNORA72 activates the Notch1/c-Myc pathway to promote stemness transformation of ovarian cancer cells.Front Cell Dev Biol2020;8:583087 PMCID:PMC7669759

[126] Park JT,Tropè CG,Shih IeM.Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.Am J Pathol2010;177:1087-94 PMCID:PMC2928943

[127] Pieterse Z,Singomat T.Ovarian cancer stem cells and their role in drug resistance.Int J Biochem Cell Biol2019;106:117-26

[128] Yang Y,Tian Y.Autophagy-driven regulation of cisplatin response in human cancers: exploring molecular and cell death dynamics.Cancer Lett2024;:216659

[129] Chen M,Tian W,Chang L.Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics.Ther Adv Med Oncol2022;14:17588359221118010 PMCID:PMC9379276

[130] Zhang X,Xia S.The emerging role of snoRNAs in human disease.Genes Dis2023;10:2064-81 PMCID:PMC10363644

[131] Naz F,Ali S,Preis E.The role of long non-coding RNAs (lncRNAs) in female oriented cancers.Cancers2021;13:6102 PMCID:PMC8656502

[132] Xu L,Sun J.Epigenetic regulation of cancer stem cells: shedding light on the refractory/relapsed cancers.Biochem Pharmacol2022;202:115110

[133] Si W,Zheng H.The role and mechanisms of action of microRNAs in cancer drug resistance.Clin Epigenetics2019;11:25 PMCID:PMC6371621

[134] Kong M,Zheng Q,Guo W.Oncogenic roles of LINC01234 in various forms of human cancer.Biomed Pharmacother2022;154:113570

[135] Jafari RM,Askari MA,Gharizadeh SMA.The role of LncRNA XIST in gynecologic cancers.CCTR2023;19:172-6

[136] Qiu J,Ni H,Xi Q.Research progress of long non-coding RNA in ovarian cancer: a narrative review.Biotarget2023;6:1

[137] Mirahmadi Y,Taheri F.MicroRNAs as biomarkers for early diagnosis, prognosis, and therapeutic targeting of ovarian cancer.J Oncol2021;2021:3408937 PMCID:PMC8553480

[138] Hosea R,Wu S.Targeting transcription factor YY1 for cancer treatment: current strategies and future directions.Cancers2023;15:3506 PMCID:PMC10340792

[139] Yang W,Kim DK,Suh DS.Therapeutic strategies for targeting ovarian cancer stem cells.Int J Mol Sci2021;22:5059 PMCID:PMC8151268

[140] Ismail A,Fathi D.The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance - a focus on signaling pathways interplay.Pathol Res Pract2022;240:154222

[141] Zhao Y,Zhang Y.Panoramic view of microRNAs in regulating cancer stem cells.Essays Biochem2022;66:345-58

[142] Singh A,Giri R.The role of microRNA-21 in the onset and progression of cancer.Future Med Chem2021;13:1885-906

[143] Najafi S.The emerging roles and potential applications of circular RNAs in ovarian cancer: a comprehensive review.J Cancer Res Clin Oncol2023;149:2211-34

[144] Sohn EJ.Differentially expression and function of circular RNAs in ovarian cancer stem cells.J Ovarian Res2022;15:97 PMCID:PMC9382745

[145] Sever R.Signaling by nuclear receptors.Cold Spring Harb Perspect Biol2013;5:a016709 PMCID:PMC3578364

[146] Weikum ER,Ortlund EA.The nuclear receptor superfamily: a structural perspective.Protein Sci2018;27:1876-92 PMCID:PMC6201731

[147] Norouzi-Barough L,Sharifi M,Jangjoo S.Molecular mechanisms of drug resistance in ovarian cancer.J Cell Physiol2018;233:4546-62

[148] Zhao L,Gustafsson JÅ.Nuclear receptors: recent drug discovery for cancer therapies.Endocr Rev2019;40:1207-49

[149] Bräutigam K,Bauerschlag DO.Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.J Cancer Res Clin Oncol2011;137:875-86

[150] Kim S,Dhanasekaran DN.Activation of LXRα/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.BMC Cancer2018;18:1232 PMCID:PMC6288854

[151] Masuyama H,Nobumoto E.Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.Int J Oncol2016;49:1211-20

[152] Wang Y,Nobumoto E,Hiramatsu Y.The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells.Biochem Pharmacol2014;90:356-66

[153] Li H,Niu C.Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.Int J Cancer2019;145:1921-34 PMCID:PMC6767785

[154] Matsumura S,Yamanouchi K.Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.Cancer Biol Ther2017;18:730-9 PMCID:PMC5663418

[155] He Y,Venkata PP.Therapeutic targeting of ovarian cancer stem cells using estrogen receptor beta agonist.Int J Mol Sci2022;23:7159 PMCID:PMC9266546

[156] Lam SS,Yam JW,Ngan HY.Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.Mol Ther2014;22:743-51 PMCID:PMC3982489

[157] Sun NK,Chang PY,Chao CC.Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.Oncotarget2014;5:11939-56 PMCID:PMC4322968

[158] Sun NK,Lu HP,Chao CC.Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: analysis of the androgen receptor.Oncotarget2015;6:27065-82 PMCID:PMC4694974

[159] Chung WM,Chang WC.Increase paclitaxel sensitivity to better suppress serous epithelial ovarian cancer via ablating androgen receptor/Aryl hydrocarbon receptor-ABCG2 axis.Cancers2019;11:463 PMCID:PMC6521308

[160] Kohli A,Chang TC,Sun NK.H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.Cancer Sci2022;113:2616-26 PMCID:PMC9357662

[161] Huang SL,Chao CCK.Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.Biochem Pharmacol2020;177:113965

[162] Huang SL,Chao CCK.TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: a potential therapeutic target to overcome taxol resistance in ovarian cancer.Biochem Pharmacol2021;186:114456

[163] Ling K,Liang S.Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.J Ovarian Res2018;11:36 PMCID:PMC5930492

[164] Wilson AJ,Roland J.TR3 modulates platinum resistance in ovarian cancer.Cancer Res2013;73:4758-69 PMCID:PMC3944084

[165] Zhang K,Chen L.Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma.Oncol Rep2020;44:909-26 PMCID:PMC7388274

[166] Wang Y,Lin Y,Yang L.Peroxisome proliferator-activated receptors as therapeutic target for cancer. J Cell Mol Med 2023;28:e17931.

[167] Han N,Yan L.Emerging insights into liver X receptor α in the tumorigenesis and therapeutics of human cancers.Biomolecules2023;13:1184 PMCID:PMC10452869

[168] Gupta D,Wang H.Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer.Clin Cancer Res2008;14:5332-40

[169] Chai SC,Wang YM.Small-molecule modulators of PXR and CAR.Biochim Biophys Acta2016;1859:1141-54 PMCID:PMC4975625

[170] Niu X,Li G,Tian Y.Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance.Int J Biol Sci2022;18:742-59 PMCID:PMC8741843

[171] Alexandrova E,Sellitto A.An overview of candidate therapeutic target genes in ovarian cancer.Cancers2020;12:1470 PMCID:PMC7352306

[172] Wang Y,Zhang XL.Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1.Mol Cell Endocrinol2014;382:791-803

[173] Wang Y,Niu XL,Zhu YQ.[Relationship of IL-6 and IL-8 secretion in epithelial ovarian cancer cell lines with their sensitivity to tamoxifen as well as MAPK, Akt and estrogen receptor phosphorylation].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi2010;26:21-4. (in Chinese)

[174] Mizushima T.The role of androgen receptor signaling in ovarian cancer.Cells2019;8:176 PMCID:PMC6406955

[175] Sun NK,Huang SL,Chao CCK.Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.J Cell Physiol2019;234:8760-75

[176] Chung WM,Chang WC,Hung YC.Androgen/androgen receptor signaling in ovarian cancer: molecular regulation and therapeutic potentials.Int J Mol Sci2021;22:7748 PMCID:PMC8304547

[177] Zou J.Site-specific delivery of cisplatin and paclitaxel mediated by liposomes: a promising approach in cancer chemotherapy.Environ Res2023;238:117111

[178] Li H,Wang Y,Qi X.Hormone therapy for ovarian cancer: emphasis on mechanisms and applications (Review).Oncol Rep2021;46:223 PMCID:PMC8424487

[179] Wu S,Lian Z.Molecular regulation of androgen receptors in major female reproductive system cancers.Int J Mol Sci2022;23:7556 PMCID:PMC9322163

[180] Zheng H,Ma S.Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.Cancer Med2020;9:5200-9 PMCID:PMC7367617

[181] Zamarin D.Novel therapeutics: response and resistance in ovarian cancer.Int J Gynecol Cancer2019;29:s16-21 PMCID:PMC7368996

[182] Han Y,Ma L.Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.Eur J Cancer2013;49:3420-30

[183] Han Y,Ma L.Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy.Cancer2013;119:3436-45

[184] Liu J,Gao Q.Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.Drug Discov Today2020;25:1232-8

[185] Deng X,Liang T,Chen X.Ovarian cancer stem cells induce the M2 polarization of macrophages through the PPARγ and NF-κB pathways.Int J Mol Med2015;36:449-54

[186] Kumar V,Kong L.The role of notch, hedgehog, and wnt signaling pathways in the resistance of tumors to anticancer therapies.Front Cell Dev Biol2021;9:650772 PMCID:PMC8100510

[187] Zhang M,Zhang Y.Research progress of estrogen receptor in ovarian cancer.Clin Exp Obstet Gynecol2023;50:199

[188] Suster N, Virant-Klun I. Presence and role of stem cells in ovarian cancer.World J Stem Cells2019;11:383-97 PMCID:PMC6682502

[189] Chung WM,Chen L.Ligand-independent androgen receptors promote ovarian teratocarcinoma cell growth by stimulating self-renewal of cancer stem/progenitor cells.Stem Cell Res2014;13:24-35

[190] Vasefifar P,Maleki LA.Nanog, as a key cancer stem cell marker in tumor progression.Gene2022;827:146448

[191] Yan H.Non-coding RNA in cancer.Essays Biochem2021;65:625-39 PMCID:PMC8564738

[192] Le P,Nana-Sinkam P.Non-coding RNAs in cancer diagnosis and therapy: focus on lung cancer.Cancers2021;13:1372 PMCID:PMC8003033

[193] Tian JH,Yu CY,Wang LB.The role of non-coding RNAs in breast cancer drug resistance.Front Oncol2021;11:702082 PMCID:PMC8473733

[194] Lan H,Zeng D.The emerging role of non-coding RNAs in drug resistance of ovarian cancer.Front Genet2021;12:693259 PMCID:PMC8430835

[195] Bai L,Zhang Y,Zhang X.Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.Exp Cell Res2018;366:161-71

[196] Wu X,Zhong W,Tian Z.The long non-coding RNA MALAT1 enhances ovarian cancer cell stemness by inhibiting YAP translocation from nucleus to cytoplasm.Med Sci Monit2020;26:e922012 PMCID:PMC7254939

[197] Long X,Hu H.Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.J Exp Clin Cancer Res2019;38:345 PMCID:PMC6686414

[198] Zhang J,Meng Q.miR-548e sponged by ZFAS1 regulates metastasis and cisplatin resistance of OC by targeting CXCR4 and let-7a/BCL-XL/S signaling axis.Mol Ther Nucleic Acids2020;20:621-38 PMCID:PMC7191130

[199] Wang DY,Cui YL.Long non-coding RNA CCAT1 sponges miR-454 to promote chemoresistance of ovarian cancer cells to cisplatin by regulation of surviving.Cancer Res Treat2020;52:798-814 PMCID:PMC7373880

[200] Xu M,Wu Y,Lu S.Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1.Mol Carcinog2019;58:577-87

[201] Shi C.LINC01118 modulates paclitaxel resistance of epithelial ovarian cancer by regulating miR-134/ABCC1.Med Sci Monit2018;24:8831-9 PMCID:PMC6292151

[202] Tan WX,Shangguan MY.Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.Sci Rep2020;10:14768 PMCID:PMC7478977

[203] Wang H,Jiang J.The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.Cell Death Dis2018;9:1103 PMCID:PMC6207559

[204] Zhao Y.lncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1/NF-κB signaling pathway.Cancer Biother Radiopharm2021;36:202-10

[205] Lin H,Lin Q.SNHG5 enhances paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.Biomed Pharmacother2020;123:109711

[206] Zhang PF,Luo JH.SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.Aging2019;11:8204-16 PMCID:PMC6814594

[207] Guo J.Long noncoding RNA LINC01125 enhances cisplatin sensitivity of ovarian cancer via miR-1972.Med Sci Monit2019;25:9844-54 PMCID:PMC6938651

[208] Zhu M,Wang X.NEAT1 knockdown suppresses the cisplatin resistance in ovarian cancer by regulating miR-770-5p/PARP1 axis.Cancer Manag Res2020;12:7277-89 PMCID:PMC7434570

[209] An J,Zhang Y.LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.Onco Targets Ther2017;10:5377-90 PMCID:PMC5691924

[210] Özeş AR,Özeş ON.NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.Oncogene2016;35:5350-61 PMCID:PMC5050052

[211] Yu Y,Tian H,Tian Y.Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy.J BUON2018;23:1396-401

[212] Wang W,Ozes A.Targeting ovarian cancer stem cells by dual inhibition of HOTAIR and DNA methylation.Mol Cancer Ther2021;20:1092-101 PMCID:PMC8172444

[213] Zhang Y,Cai E.HOTAIR maintains the stemness of ovarian cancer stem cells via the miR-206/TBX3 axis.Exp Cell Res2020;395:112218

[214] Wang J,Liu J.UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.Biochem Biophys Res Commun2018;501:1034-40

[215] Wambecke A,Morice PM.The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.Mol Oncol2021;15:3659-78 PMCID:PMC8637575

[216] Li Z,Qin Q.lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer.Mol Ther Nucleic Acids2019;17:92-101 PMCID:PMC6595407

[217] Li ZY,Dang Y.Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.Eur Rev Med Pharmacol Sci2020;24:591-603

[218] Miao JT,Chen YQ,Meng HY.LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis.Biosci Rep2019;39:BSR20182101 PMCID:PMC6609561

[219] Gu L,Liu H,Zhu M.Long noncoding RNA TUG1 promotes autophagy-associated paclitaxel resistance by sponging miR-29b-3p in ovarian cancer cells.Onco Targets Ther2020;13:2007-19 PMCID:PMC7065918

[220] Zhan FL,Yao MZ.LncRNA TUG1 facilitates proliferation, invasion and stemness of ovarian cancer cell via miR-186-5p/ZEB1 axis.Cell Biochem Funct2020;38:1069-78

[221] Liu S,Tian T.Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway.J Cell Biochem2019;120:7581-9

[222] Sajadpoor Z,Teimori H.Valproic acid promotes apoptosis and cisplatin sensitivity through downregulation of H19 noncoding RNA in ovarian A2780 cells.Appl Biochem Biotechnol2018;185:1132-44

[223] Tian X,Hou M,Teng Y.LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3.J Cancer2021;12:5712-22 PMCID:PMC8408112

[224] Zhu W,He M.SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway.J Transl Med2019;17:259 PMCID:PMC6686521

[225] Ke F,Zhai Z.LINC01234 regulates microRNA-27b-5p to induce the migration, invasion and self-renewal of ovarian cancer stem cells through targeting SIRT5.Cell Cycle2022;21:1020-33 PMCID:PMC9037434

[226] Huang R,Zhang Y.XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.Cancer Cell Int2020;20:436 PMCID:PMC7487955

[227] Xia B,Wu Y,Zhao Y.Circular RNA circTNPO3 regulates paclitaxel resistance of ovarian cancer cells by miR-1299/NEK2 signaling pathway.Mol Ther Nucleic Acids2020;21:780-91 PMCID:PMC7419276

[228] Li M,Han X.Downregulation of circNRIP1 suppresses the paclitaxel resistance of ovarian cancer via regulating the miR-211-5p/HOXC8 axis.Cancer Manag Res2020;12:9159-71 PMCID:PMC7532313

[229] Guo M,Zhao X,Zhang B.Knockdown of circular RNA Hsa_circ_0000714 can regulate RAB17 by sponging miR-370-3p to reduce paclitaxel resistance of ovarian cancer through CDK6/RB pathway.Onco Targets Ther2020;13:13211-24 PMCID:PMC7769200

[230] Zhao Z,Wang Q,Li Y.Circular RNA Cdr1as upregulates SCAI to suppress cisplatin resistance in ovarian cancer via miR-1270 suppression.Mol Ther Nucleic Acids2019;18:24-33 PMCID:PMC6726918

[231] Zhang S,Quan C.circCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252.Mol Ther Nucleic Acids2020;19:718-30 PMCID:PMC6965731

[232] Luo Y.Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.J Gynecol Oncol2020;31:e75 PMCID:PMC7440976

[233] Zheng Y,Yang S,Luan Z.CircEXOC6B suppresses the proliferation and motility and sensitizes ovarian cancer cells to paclitaxel through miR-376c-3p/FOXO3 axis.Cancer Biother Radiopharm2022;37:802-14

[234] Liu J,Xiao S,Qi Y.Circ_0000231 promotes paclitaxel resistance in ovarian cancer by regulating miR-140/RAP1B.Am J Cancer Res2023;13:872-85 PMCID:PMC10077041

[235] Ying H,Yu Q,Deng Q.CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.Drug Dev Res2022;83:512-24

[236] Wang S,Zhu G.RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.J Ovarian Res2021;14:154 PMCID:PMC8590297

[237] Sun C,Yang Z.miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.J Natl Cancer Inst2013;105:1750-8

[238] Chan JK,Kiet T.The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.Gynecol Oncol2014;132:739-44

[239] Chung WM,Chen L.MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro.Stem Cell Res Ther2013;4:88 PMCID:PMC3854706

[240] Gao Z,Bordeaux A.miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian cancer stem cells by targeting PTEN.Eur J Histochem2021;65:3186 PMCID:PMC7883108

[241] Li Z,Wang J.MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.Gynecol Oncol2010;119:125-30

[242] Sugio A,Habata S.BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.Gynecol Oncol2014;134:615-23

[243] Yao W,Huang M.MiR-30a-5p enhances cisplatin sensitivity by downregulating RIF1 in ovarian cancer.Ann Clin Lab Sci2023;53:418-26

[244] Tung SL,Hsu FC.miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.Oncogenesis2017;6:e326 PMCID:PMC5525454

[245] Qian S,Li M.Transcriptional factor Yin Yang 1 facilitates the stemness of ovarian cancer via suppressing miR-99a activity through enhancing its deacetylation level.Biomed Pharmacother2020;126:110085

[246] Huh JH,Kim K.Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.Br J Cancer2013;109:452-61 PMCID:PMC3721386

[247] Kong F,Wang Z.miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.J Huazhong Univ Sci Technolog Med Sci2011;31:543-9

[248] Zhang X,Zhao Y.Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.Acta Biochim Biophys Sin2013;45:995-1001

[249] Li X,Zeng W,Duan S.microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.Br J Cancer2017;116:66-76 PMCID:PMC5220146

[250] Xiao F,Wan Y.MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.Cancer Chemother Pharmacol2018;81:935-47

[251] Li X,Jin Y.miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.Biochem Pharmacol2019;161:98-112

[252] Belur Nagaraj A,Sekhar S.The miR-181a-SFRP4 axis regulates wnt activation to drive stemness and platinum resistance in ovarian cancer.Cancer Res2021;81:2044-55 PMCID:PMC8137569

[253] Kwon JE,Yun BS.MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: a signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.Cell Prolif2023;e13582

[254] Wang L,Lu Y.Identification of microRNA expression profiles of CD44⁺ ovarian cancer stem cells.Arch Gynecol Obstet2022;306:461-72

[255] Wang YQ,Guo RM,Yin LR.MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas.J Cell Biochem2013;114:1464-73

[256] Fang Z,Chen W.Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c.Exp Cell Res2019;382:111462

[257] Shi X,Mao X.miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells.Front Genet2018;9:555 PMCID:PMC6253938

[258] Ge G,Niu L,Ren Y.miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.Oncol Rep2016;35:1816-22

[259] Jin P,Wang R.STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance.Biosci Rep2018;38:BSR20180547 PMCID:PMC6131203

[260] Liu Y,Lin X.MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.Cancer Gene Ther2017;24:208-14

[261] Liu R,Lu S.MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2.Cancer Med2018;7:4598-609 PMCID:PMC6143943

[262] Cao L,Li F.MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.BMB Rep2018;51:456-61 PMCID:PMC6177509

[263] Chen FD,Ke SC,Zheng XY.SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.Neoplasma2018;65:915-24

[264] Zou J,Wang Q.Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1.Am J Transl Res2017;9:1357-68 PMCID:PMC5376026

[265] Arrighetti N,De Cecco L.PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells.Toxicol Appl Pharmacol2016;310:9-19

[266] Tian J,Li L.MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.Am J Transl Res2017;9:1127-38 PMCID:PMC5376004

[267] Meghani K,Detappe A.Multifaceted impact of microRNA 493-5p on genome-stabilizing pathways induces platinum and PARP inhibitor resistance in BRCA2-mutated carcinomas.Cell Rep2018;23:100-11 PMCID:PMC5908239

[268] Wu D,Mi X.Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.Arch Gynecol Obstet2018;297:699-707

[269] Liu G,Rupaimoole R.Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.J Natl Cancer Inst2015;107:djv108 PMCID:PMC4554255

[270] Bagnoli M,Valitutti M.Impairment of RAD17 functions by miR-506-3p as a novel synthetic lethal approach targeting DNA repair pathways in ovarian cancer.Front Oncol2022;12:923508 PMCID:PMC9340372

[271] Xiao S,Liu C.MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.Mol Genet Genomics2018;293:1159-67

[272] Shan L,Zhao Y.miR-600 promotes ovarian cancer cells stemness, proliferation and metastasis via targeting KLF9.J Ovarian Res2022;15:52 PMCID:PMC9063371

[273] Choi YE,Brault ME.Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer.Cell Rep2016;14:429-39 PMCID:PMC4731274

[274] Zhao H,Ding Y.MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.Oncotarget2016;7:53254-68 PMCID:PMC5288183

[275] Wu DD,Meng XN,Zong ZH.MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.Tumour Biol2016;37:10499-506

[276] Yu JL.MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.Eur Rev Med Pharmacol Sci2020;24:1688-96

[277] García-Vázquez R,Ruiz-García E.let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer.Oncol Rep2018;39:3086-94

[278] Xiao M,Cai L.Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.J Ovarian Res2017;10:24 PMCID:PMC5379542

[279] Xiao M,Xie L.Let-7e suppresses DNA damage repair and sensitizes ovarian cancer to cisplatin through targeting PARP1.Mol Cancer Res2020;18:436-47